Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oncolytic HSV-1 JNJ-87704916

A recombinant oncolytic herpes simplex virus type 1 (HSV-1), with potential oncolytic and antineoplastic activities. Upon intratumoral administration, oncolytic HSV-1 JNJ-87704916 preferentially infects and replicates in tumor cells causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	oncolytic virus JNJ-87704916
Code name:	JNJ 87704916 JNJ-87704916 JNJ87704916

oncolytic HSV-1 JNJ-87704916

Search NCI's Drug Dictionary